Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.

ABSTRACT:

Introduction

Consensus definitions for clinical remission and super-response were recently established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed monoclonal antibody for severe, uncontrolled asthma; efficacy and safety were demonstrated in previous pivotal phase 3 trials (SIROCCO, CALIMA, ZONDA). This analysis applied a composite remission definition to characterize individual responses to benralizumab after 6 and 12 months.

Methods

In previous phase 3 studies, eligible patients were those with severe, uncontrolled asthma receiving medium- or high-dosage inhaled corticosteroids plus long-acting β₂-agonists. This post hoc analysis included patients randomized to the approved benralizumab dose and not receiving oral corticosteroid

SUBMITTER: Menzies-Gow A 

PROVIDER: S-EPMC9056458 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature